Jeb Keiper has served as Nimbus Therapeutics’ CEO since 2018, joined in 2014 previously serving as CBO and CFO. Since joining, Mr. Keiper has overseen the discovery and development of three programs into clinical testing across a range of indications, raised over $600M in equity funding, executed deals worth over $7B, and returned over $4B in gains back to equity holders. Jeb is an independent board director for Cardurion Pharmaceuticals, ROME Therapeutics, and Life Science Cares. Prior to Nimbus, Jeb spent a decade at GSK, ultimately as VP of Oncology BD. Jeb began his career at Pfizer as a bench chemist. He received four degrees from MIT in Chemistry, Chemical Engineering, and an MBA.